GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, ...
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
Bas Vorsteveld will oversee the consumer health company’s Aveeno, Johnson’s Baby, Listerine and Neutrogena brands ...
GSK plans to buy back £2 billion (S$3.4 billion) of shares as it raised its long-term growth outlook on optimism around its ...
Arizona Attorney General Kris Mayes on Thursday sued pharmaceutical manufacturer GlaxoSmithKline for engaging in deceptive and unfair practices ...
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.
Stockhead on MSN6d
Biocurious: Consumer health minnow Wellnex Life gears up for company-making EurotripWellnex Life (ASX:WNX) managing director Zack Bozinovski admits that local investors don’t fully understand the power and ...
The lawsuit filed Thursday in Maricopa County Superior Court by Arizona Attorney General Kris Mayes, citing the Arizona Consumer ... says, "GSK put corporate greed ahead of the health and safety ...
The lawsuit filed in Maricopa County Superior Court contends GlaxoSmithKline's actions violate the Arizona Consumer Fraud Act ...
Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.
GlaxoSmithKline would consider buying Pfizer’s consumer health business – but only if the price is right, according to the company's chief executive. Emma Walmsley has also been busy shaking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback